Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease;Optimización del tratamiento inmunomodulador con azatioprina o 6-mercaptopurina en pacientes con enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 30, Issue 9, 2007, Pages 511-517

  Bastida Paz, Guillermo ^a   Nos Mateu, Pilar ^a   Aguas Peris, Mariam ^a   Beltrán Niclós, Belén ^a   Rodríguez Soler, María ^a   Ponce García, Julio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BONE MARROW APLASIA; CROHN DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRURITUS; RELAPSE; REMISSION; SIDE EFFECT; SKIN DEFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 36049047688     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13111681     Document Type: Article

References (26)

1. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1-16.
2. Weersma RK, Peters FT, Oostenbrug LE, Van den Berg AP, Van Haastert M, Ploeg RJ, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843-50.
3. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-5.
4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-87.
5. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170 Suppl:2-6.
6. Gasche C, Scholmerich J, Brynskov, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
7. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
8. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-9.
9. De Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2004;16:207-12.
10. Marion JF. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:116-7.
11. Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy. Gastroenterology. 2004;127:1558-64.
12. López-Sanroman A, Bermejo F, Carrera E, García-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004;20:161-6.
13. Lucena MI, Camargo R, Andrade RJ, Pérez-Sánchez CJ, Sánchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123-30.
14. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:775-82.
15. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699-708.
16. Moss AC, Farrell RJ. Lymphoma risk with azathioprine/6-MP therapy-read beyond the headlines. Gastroenterology. 2006;130:1363-4.
17. Gisbert JP, González-Lama Y, Mate J. Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol Hepatol. 2006;29:568-83.
18. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:1-16.
19. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;15:132-42.
20. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;26:876-85.
21. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
22. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-8.
23. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol. 1994;89:362-6.
24. Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2001;13:1073-6.
25. Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brandt SR, et al. Toward and integrated clinical, molecular, and serological classification of inflammatory bowel disease: report or a working party of the Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5.
26. Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn's disease. Dig Dis Sci. 2004;49:1771-6. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study